Head to Head Comparison: Ero Copper (NYSE:ERO) and DiaSorin (OTCMKTS:DSRLF)

DiaSorin (OTCMKTS:DSRLF) and Ero Copper (NYSE:ERO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Profitability

This table compares DiaSorin and Ero Copper’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DiaSorin	N/A	N/A	N/A
Ero Copper	14.23%	10.68%	5.46%

Analyst Recommendations

This is a summary of current ratings for DiaSorin and Ero Copper, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaSorin	0	1	0	0	2.00
Ero Copper	0	1	3	1	3.00

Ero Copper has a consensus target price of $32.00, suggesting a potential upside of 65.55%. Given Ero Copper’s stronger consensus rating and higher possible upside, analysts plainly believe Ero Copper is more favorable than DiaSorin.

Earnings & Valuation

This table compares DiaSorin and Ero Copper’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaSorin	$1.43 billion	N/A	$253.82 million	N/A	N/A
Ero Copper	$427.48 million	4.67	$92.80 million	$0.65	29.74

DiaSorin has higher revenue and earnings than Ero Copper.

Institutional & Insider Ownership

71.3% of Ero Copper shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

DiaSorin has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Ero Copper has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Summary

Ero Copper beats DiaSorin on 9 of the 11 factors compared between the two stocks.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

About Ero Copper

Ero Copper Corp. engages in the exploration, development, and production of mining projects in Brazil. The company is involved in the production and sale of copper concentrate from the Caraíba operations located in the Curaçá Valley, northeastern Bahia state, Brazil, as well as gold and silver by-products. It also holds 100% interests in the Tucumã project, a copper development project located within southeastern Pará state; and the Xavantina Operations located in Mato Grosso state. Ero Copper Corp. was incorporated in 2016 and is headquartered in Vancouver, Canada.